Categories: DNANewsPharmaceutical

Avalyn to Provide Keynote Presentation at the Formulation & Delivery U.S. 2023 Conference

SEATTLE, Sept. 29, 2023 (GLOBE NEWSWIRE) — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary diseases, today announced that Stephen Pham, Ph.D., senior vice president of product development at Avalyn, will give a keynote address during the Formulation & Delivery U.S. 2023 Conference being held October 2-3, 2023, in San Diego, CA. Dr. Pham will discuss the development of inhaled drug-device combinations for the treatment of pulmonary fibrosis.

Details for Dr. Pham’s keynote address are as follows:

Keynote Title: Bringing Beautiful Breaths of Life to Patients with Pulmonary Fibrosis
Date and Time: Monday, October 2, 2023, at 8:55 a.m. PT
Location: Doubletree by Hilton San Diego Mission Valley, Conference Room 4

Full program details can be accessed via the conference website.

About Avalyn Pharma
Avalyn is a biopharmaceutical company developing targeted therapeutics for the treatment of rare respiratory diseases including pulmonary fibrosis and other interstitial lung diseases (ILD). Pulmonary fibrosis is characterized by scarring, decline in lung function, reduced exercise capacity and quality of life, and is associated with increased mortality. Currently approved therapeutic options slow pulmonary fibrosis progression but are associated with significant toxicities that restrict their use and dosing. Avalyn is developing a pipeline of new inhaled formulations of approved medicines designed to reduce systemic exposure and deliver medication to the site of disease. Avalyn’s pipeline is led by AP01, an optimized inhaled formulation of pirfenidone, which has been assessed in 150 individuals with different forms of pulmonary fibrosis and demonstrated clinical proof-of-concept with improved efficacy and safety over existing therapies. For more information, please visit avalynpharma.com.

Contacts:
Alex Straus
THRUST Strategic Communications
alex@thrustsc.com

Cara Mayfield
THRUST Strategic Communications
cara@thrustsc.com

Staff

Recent Posts

Predictmedix AI Announces Closing of Final Tranche of Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - December 5, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink:…

2 hours ago

Techficient Launches Surefire, Its Proprietary Modern Underwriting Engine

BOISE, Idaho, Dec. 5, 2025 /PRNewswire/ -- Techficient, a leading innovator in Insurtech solutions, announces the…

2 hours ago

Clinical Education Alliance Becomes Decera Clinical, Delivering Education, Insights, and Communications

Company brings its Scientific Activation™ mission to life at ASH Annual Meeting following November rebrand RESTON,…

2 hours ago

Shrub Oak International School Reinforces Unwavering Commitment to Student Safety and Security

MOHEGAN LAKE, N.Y., Dec. 5, 2025 /PRNewswire/ -- Shrub Oak International School today announced enhanced…

2 hours ago

‘I’D RATHER GET A ROOT CANAL’: US WORKERS DREAD THE OFFICE HOLIDAY PARTY

National poll reveals 27% of workers prefer dental work over office celebrations as workplace disconnection…

2 hours ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA…

2 hours ago